Aurora kinase inhibitor patents and agents in clinical testing: an update (2009-10). (Q37876882)

24 August 2017

1 reference

title

Aurora kinase inhibitor patents and agents in clinical testing: an update (2009-10). (English)

1 reference

24 August 2017

0 references

Mohane Selvaraj Coumar

2

0 references

Hsing-Pang Hsieh

object named as

Hsing-Pang Hsieh

4

0 references

author name string

Chun Hei Antonio Cheung

1

1 reference

24 August 2017

Jang-Yang Chang

3

1 reference

24 August 2017

language of work or name

English

0 references

publication date

1 June 2011

1 reference

Expert Opinion on Therapeutic Patents

24 August 2017

1 reference

24 August 2017

21

1 reference

24 August 2017

6

1 reference

24 August 2017

857-884

1 reference

Probing the dynamics and functions of aurora B kinase in living cells during mitosis and cytokinesis

24 August 2017

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2011.574614

Aurora A is essential for early embryonic development and tumor suppression

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2011.574614

Frequent overexpression of Aurora Kinase A in upper gastrointestinal adenocarcinomas correlates with potent antiapoptotic functions

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2011.574614

Overexpression of aurora B kinase (AURKB) in primary non-small cell lung carcinoma is frequent, generally driven from one allele, and correlates with the level of genetic instability

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2011.574614

Constitutive phosphorylation of aurora-a on ser51 induces its stabilization and consequent overexpression in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2011.574614

VX-680, a potent and selective small-molecule inhibitor of the Aurora kinases, suppresses tumor growth in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2011.574614

VX-680 inhibits Aurora A and Aurora B kinase activity in human cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2011.574614

The Aurora kinase inhibitor VX-680 induces endoreduplication and apoptosis preferentially in cells with compromised p53-dependent postmitotic checkpoint function

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2011.574614

AZD1152, a selective inhibitor of Aurora B kinase, inhibits human tumor xenograft growth by inducing apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2011.574614

Antitumor activity of MLN8054, an orally active small-molecule inhibitor of Aurora A kinase

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2011.574614

GSK1070916, a potent Aurora B/C kinase inhibitor with broad antitumor activity in tissue culture cells and human tumor xenograft models.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2011.574614

Biochemical characterization of GSK1070916, a potent and selective inhibitor of Aurora B and Aurora C kinases with an extremely long residence time1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2011.574614

MLN8054, a small-molecule inhibitor of Aurora A, causes spindle pole and chromosome congression defects leading to aneuploidy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2011.574614

SNS-314, a pan-Aurora kinase inhibitor, shows potent anti-tumor activity and dosing flexibility in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2011.574614

The Aurora kinase inhibitor SNS-314 shows broad therapeutic potential with chemotherapeutics and synergy with microtubule-targeted agents in a colon carcinoma model

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2011.574614

The aurora B kinase inhibitor AZD1152 sensitizes cancer cells to fractionated irradiation and induces mitotic catastrophe

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2011.574614

Advances in Aurora kinase inhibitor patents

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2011.574614

The discovery of the potent aurora inhibitor MK-0457 (VX-680).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2011.574614

Phase I dose escalation study of MK-0457, a novel Aurora kinase inhibitor, in adult patients with advanced solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2011.574614

Efficacy of MK-0457 and in combination with vorinostat against Philadelphia chromosome positive acute lymphoblastic leukemia cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2011.574614

Aurora-A down-regulates IkappaBalpha via Akt activation and interacts with insulin-like growth factor-1 induced phosphatidylinositol 3-kinase pathway for cancer cell survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2011.574614

Combination of nutlin-3 and VX-680 selectively targets p53 mutant cells with reversible effects on cells expressing wild-type p53.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2011.574614

Simultaneous determination of AZD1152 (prodrug) and AZD1152-hydroxyquinazoline pyrazol anilide by reversed phase liquid chromatography

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2011.574614

Aurora kinase inhibitor AZD1152 negatively affects the growth and survival of HTLV-1-infected T lymphocytes in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2011.574614

Antineoplastic effects of an Aurora B kinase inhibitor in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2011.574614

The selective Aurora B kinase inhibitor AZD1152 as a novel treatment for hepatocellular carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2011.574614

The topoisomerase I poison CPT-11 enhances the effect of the aurora B kinase inhibitor AZD1152 both in vitro and in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2011.574614

Inhibition of Aurora B kinase sensitizes a subset of human glioma cells to TRAIL concomitant with induction of TRAIL-R2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2011.574614

Clinical evaluation of AZD1152, an i.v. inhibitor of Aurora B kinase, in patients with solid malignant tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2011.574614

BPR0L075, a novel synthetic indole compound with antimitotic activity in human cancer cells, exerts effective antitumoral activity in vivo.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2011.574614

Identification of genes that confer tumor cell resistance to the aurora B kinase inhibitor, AZD1152.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2011.574614

PHA-739358, a potent inhibitor of Aurora kinases with a selective target inhibition profile relevant to cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2011.574614

1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazoles: identification of a potent Aurora kinase inhibitor with a favorable antitumor kinase inhibition profile.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2011.574614

Aurora kinase inhibitor PHA-739358 suppresses growth of hepatocellular carcinoma in vitro and in a xenograft mouse model

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2011.574614

A phase I dose-escalation study of danusertib (PHA-739358) administered as a 24-hour infusion with and without granulocyte colony-stimulating factor in a 14-day cycle in patients with advanced solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2011.574614

Phase I pharmacokinetic and pharmacodynamic study of the aurora kinase inhibitor danusertib in patients with advanced or metastatic solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2011.574614

Aurora kinase A inhibition leads to p73-dependent apoptosis in p53-deficient cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2011.574614

MLN8054, an inhibitor of Aurora A kinase, induces senescence in human tumor cells both in vitro and in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2011.574614

Drug-resistant aurora A mutants for cellular target validation of the small molecule kinase inhibitors MLN8054 and MLN8237

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2011.574614

A novel Aurora-A kinase inhibitor MLN8237 induces cytotoxicity and cell-cycle arrest in multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2011.574614

Water-soluble prodrugs of an Aurora kinase inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2011.574614

2-Aminobenzimidazoles as potent Aurora kinase inhibitors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2011.574614

Discovery of GSK1070916, a potent and selective inhibitor of Aurora B/C kinase

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2011.574614

PF-03814735, an orally bioavailable small molecule aurora kinase inhibitor for cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2011.574614

Discovery of N-phenyl-4-(thiazol-5-yl)pyrimidin-2-amine aurora kinase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2011.574614

Assessment of the in vivo antitumor effects of ENMD-2076, a novel multitargeted kinase inhibitor, against primary and cell line-derived human colorectal cancer xenograft models

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2011.574614

Fragment-based discovery of the pyrazol-4-yl urea (AT9283), a multitargeted kinase inhibitor with potent aurora kinase activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2011.574614

Activity of the multitargeted kinase inhibitor, AT9283, in imatinib-resistant BCR-ABL-positive leukemic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2011.574614

Preclinical characterization of Aurora kinase inhibitor R763/AS703569 identified through an image-based phenotypic screen

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2011.574614

MK-5108, a highly selective Aurora-A kinase inhibitor, shows antitumor activity alone and in combination with docetaxel

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2011.574614

Preclinical evaluation of AMG 900, a novel potent and highly selective pan-aurora kinase inhibitor with activity in taxane-resistant tumor cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2011.574614

Outcomes for children and adolescents with cancer: challenges for the twenty-first century

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2011.574614

Identification, SAR studies, and X-ray co-crystallographic analysis of a novel furanopyrimidine aurora kinase A inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2011.574614

Fast-forwarding hit to lead: aurora and epidermal growth factor receptor kinase inhibitor lead identification

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2011.574614

Targeted anti-mitotic therapies: can we improve on tubulin agents?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2011.574614

Aurora kinase inhibitors: novel small molecules with promising activity in acute myeloid and Philadelphia-positive leukemias.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2011.574614

Design of chimeric histone deacetylase- and tyrosine kinase-inhibitors: a series of imatinib hybrides as potent inhibitors of wild-type and mutant BCR-ABL, PDGF-Rbeta, and histone deacetylases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2011.574614

Phase I Study of the Selective Aurora A Kinase Inhibitor MLN8054 in Patients with Advanced Solid Tumors: Safety, Pharmacokinetics, and Pharmacodynamics

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2011.574614

10.1517/13543776.2011.574614

21 January 2018

Identifiers

DOI

1 reference

release_nbkyv626urff7oneyrzmkuzxp4

24 August 2017

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/nbkyv626urff7oneyrzmkuzxp4

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference